Idiopathic Generalized Epilepsy
Neurology·MeSH: Epilepsy
Prevalence
700.0 / 100K
Incidence
48.0 / 100K/yr
2 drugs in development·2 companies·2 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| levetiracetam | Mylan II B.V. (MYL) |
Phase 3(1)
| Drug | Company |
|---|---|
| rns system | Neuropace Inc. (NPCE) |
Compare drugs
Frequently asked questions
How many drugs are in development for Idiopathic Generalized Epilepsy?
BioSniper tracks 2 drugs in development for Idiopathic Generalized Epilepsy across 2 companies.
How many clinical trials target Idiopathic Generalized Epilepsy?
There are 2 clinical trials targeting Idiopathic Generalized Epilepsy tracked by BioSniper.
What is the prevalence of Idiopathic Generalized Epilepsy?
The estimated prevalence of Idiopathic Generalized Epilepsy is approximately 700.0 per 100,000 population.
Deep-dive into Idiopathic Generalized Epilepsy
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis